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Osteosarcoma is one among the most common neoplasms in dogs. Current treatments show limited efﬁcacy and
fail to prevent metastasis. Conditionally replicative adenoviruses (CRAd) replicate exclusively in targeted tumor
cells and release new virus particles to infect additional cells. We proposed that OC-CAVE1 (CAV2 with the E1A
promoter replaced with the osteocalcin promotor) may also enhance existing immunity against tumors by
overcoming immune tolerance via exposure of new epitopes and cytokine signaling. Eleven client-owned dogs
with spontaneously occurring osteosarcomas were enrolled in a pilot study. All dogs were injected with OCCAVE1 following amputation of the affected limb or limb-sparing surgery. Dogs were monitored for viremia
and viral shedding. There was minimal virus shedding in urine and feces by the 6th day and no virus was present
in blood after 4 weeks. CAV-2 antibody-titers increased in all of the patients, post-CRAd injection. Immunological
assays were performed to monitor 1) humoral response against tumors, 2) levels of circulatory CD11c þ cells, 3)
levels of regulatory T cells, and 4) cytotoxic activity of tumor speciﬁc T cells against autologous tumor cells
between pre-CRAd administration and 4 weeks post-CRAd administration samples. Administration of the CRAd
OC-CAVE1 resulted in alteration of some immune response parameters but did not appear to result in increased
survival duration. However, 2 dogs in the study achieved survival times in excess of 1 year. Weak replication of
OC-CAVE1 in metastatic cells and delay of chemotherapy following CRAd treatment may contribute to the lack of
immune response and improvement in survival time of the clinical patients.

1. Introduction
Appendicular osteosarcoma (OSA) is a common neoplasm in dogs,
with at least 8,000–10,000 cases diagnosed per year, accounting for
5–6% of all canine malignancies and approximately 80% of all canine
bone neoplasms [1, 2]. The disease usually occurs in middle to older
aged, large or giant breed dogs [1, 3, 4]. Current treatments consist of
palliative amputation or limb-sparing techniques combined with
platinum-based chemotherapy. Amputation alone results in a median
survival time of approximately 6 months, which increases to approximately one year if chemotherapy is added, but most dogs still succumb to
metastatic disease [2, 4, 5]. Therefore, a different strategy is needed to

improve survival times by eradicating the remaining neoplastic cells and,
in particular, focusing on eradication of micrometastatic disease.
Oncolytic viruses are a promising tool for cancer gene therapy.
Adenoviral (Ad) vectors are among the most commonly used oncolytic
vectors. Conditionally replicative adenoviruses (CRAd) are designed so
that virus replicates only in the target tissue, thus ensuring speciﬁcity of
any observed cytopathic effects (CPE) to those target cells. Replication of
the CRAd in turn releases thousands of new virus particles which may go
on to infect new tumor cells [6]. CRAds have also been proposed as a
potent therapy for eradication of cancer stem cells (CSC) [7, 8]. CSCs are
quiescent cells with a high tumorigenic potential and are resistant to
many cancer therapies. Therefore, it has been proposed that CSCs are
responsible for causing tumor micro-metastases and relapse [9].
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A group of 11 client-owned canine patients with spontaneously
occurring OSA were enrolled in the study (Table 1). Written informed
consent to enroll the animals was obtained from the owners of the animals. Enrollment of animals was approved by the Clinical Research Review Committee of the College of Veterinary Medicine (CRRC) and the
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2.1. Patient admission and CRAD injection

Breed

2. Materials and methods

Patient

Table 1. Demographics of all the patients enrolled in the study.

Location

Suspected Metastasis at the
time of CRAd Administration

Surgery

Suspected Metastasis at
the Terminal Stage

Cause Of Death

A further beneﬁt of oncolytic viruses in the treatment of cancer is that
they may be able to enhance existing immunity to tumors [10]. Listeria
vaccine induced HER2/neu þ appendicular OSA-speciﬁc immunity,
reduced the metastatic incidences, and increased the overall survival in
spontaneous clinical canine patients [11]. Oncolysis due to CRAds can
result in overcoming immune tolerance and generating an immune
response to tumor cells [6, 12]. Immune cell recruitment to the tumor
mass can result from both the lysis of the tumor cell and the release of
cytokines from infected cells [10, 13]. It is well documented that there is
a robust immune response to many tumors, evident by inﬁltrating immune cells including T cells, B cells, natural killer (NK) cells and dendritic cells (DCs) [10]. An increase in the number of DCs in the site of the
tumor has been suggested as having beneﬁcial anti-tumor activity and
resulted in the development of DC based vaccine therapies for a number
of cancers [13]. However, the tumor microenvironment is inherently
immunosuppressive due to the presence of regulatory T cells (T-regs),
which are present to varying degrees in different types of neoplasms.
Circulating T-regs are increased in dogs with cancer and increased
numbers of T-regs are associated with a poorer prognosis and decreased
survival time in canine OSA patients [14].
Previously, we developed a canine CRAd (OC-CAVE1) based on
canine adenovirus type 2 (CAV2) for use in canine OSA, [15]. CAV2 is
commonly used as a vaccine against CAV1, the agent of canine hepatitis.
The CRAd OC-CAVE1 was constructed by replacing the wild type promoter of the CAV2 E1A gene with the osteocalcin promoter that restricts
its replication to canine OSA cells and causes CPE only in these cells [16].
OC-CAVE1 also shows signiﬁcant anti-tumor activity against established
canine OSA xenografts in a nude mouse model [16].
Safety of OC-CAVE1 was determined by injecting virus intravenously
into 3 normal dogs and 3 transiently immunosuppressed dogs. All dogs
had pre-existing anti-CAV2 antibody titers due to CAV2 vaccination.
Immunosuppression was employed because it was hypothesized that an
anamnestic response to CAV2 would result in faster elimination of virus
and thus reduce ability of CRAd to infect metastatic cells. However, no
change in circulating CRAd viral numbers was observed in immunosuppressed dogs when compared to non-immunosuppressed dogs and the
only adverse event noted was a short-lived lymphopenia, consistent with
viral infections [15]. Based on the data in normal dogs, a preliminary
safety study was initiated to determine the safety of virus in 4 dogs
affected with OSA (data unpublished). The longest-lived dog in this study
(25 months) developed pulmonary nodules at 1 year after treatment.
Histopathologic examination of the nodule showed caseous necrosis.
While there are many possible causes of pulmonary caseous necrosis, an
intriguing possibility was that this dog had an immune response to
tumor, walling off metastatic tumor in the lung, perhaps in response to
OC-CAVE1 infection and immune stimulation. The preliminary safety
study was not designed to evaluate this question, thus the present study
was initiated to further examine this hypothesis.
Given that OC-CAVE1 can be safely administered to dogs, can be
speciﬁcally engineered to replicate only in tumor cells, may target CSCs,
and more importantly potentially generate an enhanced immune
response to tumor, we started an expanded pre-clinical study in canine
OSA patients. Ten patients were fully enrolled over the 2-year study
period. The ﬁndings from this pilot experiment, focused on the immunologic results of CRAd therapy for canine OSA, are summarized in this
report.

Euthanasia for OSA

Heliyon 7 (2021) e06210
Euthanasia not for OSA

P. Agarwal et al.

P. Agarwal et al.

Heliyon 7 (2021) e06210

centrifugation and collected in a 15ml conical tube. An equal amount
of 1X PBS was added and the cells centrifuged at 700 x g for 10 min. The
supernatant was removed, and the white cell pellet was re-suspended in
5ml 1X PBS and centrifuged again at 700 x g for 10 min. After centrifugation, the supernatant was removed and the PBMC (Peripheral
Mononuclear Blood Cells) cell pellet was re-suspended in complete RPMI
(Roswell Park Memorial Institute medium, Corning) with penicillin (100
IU/ml, Corning), streptomycin (100 ug/ml, Corning), amphotericin B
(0.5ug/ml, Corning) and 10% FBS (Fetal bovine serum, Sigma). PBMCs
were counted and then cryopreserved as described above in freezing
media (10% DMSO þ Complete RPMI media) for further experiments.

Auburn University Institutional Animal Care and Use Committee
(IACUC). All patient dogs were pre-evaluated and had conﬁrmed the
diagnosis of OSA before being accepted into the study. All dogs were prevaccinated for CAV. All dogs except Patient 1 underwent limb amputation at the Wilford and Kate Bailey Small Animal Teaching Hospital.
Patient 1 underwent limb-sparing surgery. Following 3 days' recovery in
the ICU after limb amputation surgery, 2  1012 CRAD virus particles of
OC-CAVE1 (generously gifted by Dr. David T Curiel and Dr. Igor Dmitriev) were injected into the dog's cephalic vein over approximately 5
min. Viral stocks were stored at -85  C and thawed on ice immediately
prior to use. Virus doses were diluted to a ﬁnal volume of 5 ml in ice cold
Phosphate buffered saline (PBS). The dogs were isolated and monitored
for signs of shock or other manifestations of toxicity for 6 days, using
VCOG criteria [17]. This included monitoring the dogs' vital signs by
hospital staff and veterinary students (body temperature, pulse rate, and
respiratory rate) at 15 min pre-injection and 15 min, 30 min, and at 1, 2,
4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 144 h post-injection.
Blood (2ml) and free catch urine (1ml) and feces were collected every 12
h post-injection for 6 days for PCR determination of CRAd concentration
in these materials. Blood (2ml) samples were also taken at 48 h and 144 h
post-injection for complete blood count (CBC) and blood chemistry
analysis by the Auburn University Clinical Pathology Laboratory. At the
end of the isolation period, the dogs were released to their owners. Dogs
returned to the hospital at approximately monthly intervals for examination and the ﬁnal outcome of the dogs was determined by either examination of the clinical record or direct contact with the owner.
Patient information was collected from the electronic medical record
at College of Veterinary Medicine at Auburn University. This information
was recorded throughout the study. Patients 3 and 4 did not return to
College of Veterinary Medicine at Auburn University for terminal stage
care, and therefore, there is limited or no information regarding their
terminal stage diagnosis and condition.

2.4. Anti-CAV2 titers
Plasma collected from blood drawn before and post-CRAD administration was sent to the Virology Laboratory at College of Veterinary
Medicine, Auburn University for CAV-2 neutralizing antibody titers.
CAV2 titers were determined by serum neutralization using 100 TCID of
a CAV2 vaccine derived virus on Fieldsteel canine kidney cells.
2.5. DNA extraction, Primer Design, and Quantitative PCR
DNA was extracted from blood, feces, and urine samples using
QIAamp DNA mini kit, QIAamp Fast DNA Stool mini kit, and QIAamp
Viral RNA mini kit respectively, according to the manufacturer's instructions. DNA quality was assessed using nanodrop spectrophotometer.
The concentration of DNA was determined by absorbance at 260 nm. The
sequences to amplify CAV2-E1B gene were the forward primer
GCTTGCTACATTATTGGTAA, reverse primer CAAGGTGTTTCTTTCACTAA, and probe 6FAM-CTAACCTGCCTGCTGGAGAA-TAMRA. TaqMan
primers and probes were designed by the DNA Star software and
commercially synthesized (Euroﬁns Genomics). The qPCR master mix
was designed with a ﬁnal volume of 15 ul per reaction containing 1X Sso
Advanced™ Universal Probes Supermix (BioRad), 250 nM forward
primer, 250 nM reverse primer, and 250 nM probe. For the assay, known
amounts of OC-CAVE1 template DNA (108, 106, 104, and 102 copies)
were ampliﬁed to generate a standard curve for quantiﬁcation of the OCCAVE1 copy numbers in the experimental samples. Five microliters (5ul)
of the sample was added to 15ul of PCR master mix in each reaction well.
PCR was performed in 96 well plates. Thermal cycling conditions were 3
min at 95  C and 40 cycles of 5 s at 95  C and 10 s at 54  C. qPCR was
performed using a Bio-Rad iCycler iQ Multicolor Real-Time PCR machine. PCR products were puriﬁed using GeneJet gel extraction kit
(Thermo) according to the manufacturer's instructions and identity was
conﬁrmed by sequencing (Euroﬁns MWG Operon).

2.2. Autologous osteosarcoma cell culture
In order to generate autologous tumor cells for immunological analyses, the amputated limb was collected from surgery and small tumor
pieces were removed and diced into 1 mm cubes. The remaining tumor
mass was submitted for histopathological conﬁrmation of the diagnosis
of OSA. The tumor cubes were cultured in complete DMEM (Dulbecco's
Modiﬁed Eagle's Medium, Corning) with penicillin (300 IU/ml, Corning),
streptomycin (300 ug/ml, Corning), amphotericin B (1.5ug/ml, Corning), and 20% FBS (fetal bovine serum, Sigma) at 37  C in 6 well plates as
tumor explants. The media was changed weekly until cells were 80–90%
conﬂuent. Adherent cells were passaged two to four times before cryopreservation. Cells were cryopreserved in Freezing medium (10% DMSO
þ complete DMEM media) by gradually cooling the cells to -80  C.
Cryopreserved cells were stored in liquid nitrogen. Cryopreserved OSA
cells were thawed at 37  C. OSA cells were cultured in complete DMEM
(Dulbecco's Modiﬁed Eagle's Medium, Corning) with penicillin (100 IU/
ml, Corning), streptomycin (100 ug/ml, Corning), amphotericin B
(0.5ug/ml, Corning), and 20% FBS (fetal bovine serum, Sigma) at 37  C.

2.6. Protein extraction and western blot
Cryopreserved primary OSA cells were thawed and cultured in T75
culture ﬂasks in complete DMEM media (as described above). At
approximately 80% conﬂuence, the cells were washed with cold 1X PBS.
1ml RIPA (Radioimmunoprecipitation assay) lysis and extraction buffer
(Thermo Scientiﬁc) along with 1X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo) was added to the cells. Cells were lysed using
one cycle of freeze/thaw and passage through 21-gauge and 23-gauge
needles. All steps were performed on ice. The cell lysate was centrifuged at ~14,000 x g for 15 min at 4  C. The supernatant was transferred
to a new tube and stored at -20  C. Supernatants were assayed for protein
concentration using a Bicinchoninic Acid Assay (BCA200 protein assay
kit, Pierce). For normalization purposes equal starting volumes of protein
cell lysates, extracted from OSA cells, were incubated in boiling water in
Lane Marker Reducing Sample Buffer (Pierce) for 10 min before loading
onto a polyacrylamide gel (4–20% and 8–16% precise™ protein gels,
Pierce) along with Kaleidoscope markers (range 10–250 kDa, BioRad).
Electrophoresis was run in Tris–HEPES–SDS running buffer (Pierce) for 1
h at 100 V and proteins were transferred to PVDF membranes

2.3. Blood draw and PBMC isolation
50 ml blood was drawn from the cephalic vein of all enrolled dogs
prior to CRAd administration (day 0) and at 4 weeks after virotherapy.
Blood was collected in EDTA tubes to prevent coagulation. 2ml blood was
saved for monitoring CRAD levels pre and post CRAD injection by
quantitative PCR. Blood was centrifuged at 450 x g for 30 min at room
temperature. After centrifugation, the top plasma layer was collected and
saved at -80  C. The middle buffy coat layer was collected and transferred
to 15 ml conical tubes (VWR). 2 ml of 1X PBS (Corning) was slowly added
to the buffy coat. 5 ml of Histopaque 1077 (Sigma) was layered below the
buffy layer and PBS mix. The layered suspension was centrifuged at 700 x
g for 30 min. The cellular middle white layer was extracted post3
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2.7.2. Antigen presenting cells
Frozen PBMCs were thawed at 37  C and were rested for 30 min at 4

C (with caps cracked open). Cells were blocked in dog block (1X PBS þ
10%NDS þ canine Fc Receptor binding inhibitor; Thermo Cat# 14-916242) for 30 min at room temperature. Cells were washed in 1X PBS and
stained with ﬁxable viability dye (Biolegend; Cat# 423111) and incubated for 30 min at room temperature. Cells were washed again with 1X
PBS and stained with anti-canine CD11c antibody (Biorad, Cat#
MCA1778S) tagged with Zenon ® Alexa Fluor® 700 (Thermo, Cat#
Z25011) and incubated for 30 min at room temperature. Cells were
washed and analyzed for CD11c positive cells by ﬂow cytometry.

(Immobilone1-P Transfer Membrane, Millipore) using transfer buffer
(25mM bicine, 25mM Tris-base, 10% Methanol) for 1 h at 100 V. The
membrane was washed with 1X wash buffer (1X PBS and 0.1% v/v
Tween 20). The membrane was blocked with blocking buffer (5% non-fat
milk powder dissolved in 1X wash buffer) for 2 h at room temperature.
The membrane was incubated with autologous blood plasma (1:100)
overnight at 4  C. The membrane was washed with wash buffer 3 times
for 10 min each at room temperature. The membrane was incubated with
goat anti-dog IgG (H þ L) -HRP secondary antibody (1:10,000; Sigma) for
1 h at room temperature. The membrane was washed again 3 times for 10
min each at room temperature. Western blot analysis was performed
using WesternSure Chemiluminescence Reagent (LICOR) according to
the manufacturer's instructions. Membranes were scanned digitally using
C-Digit Blot Scanner (LICOR).

2.7.3. Regulatory T cells
Frozen PBMCs were prepared as described for antigen presenting cells,
above. Cells were washed in 1X PBS and stained with ﬁxable viability dye
(Biolegend; Cat# 423111) and incubated for 30 min at room temperature.
Cells were washed again with 1X PBS and stained with anti-canine
CD4:Alexa Fluor® 488 antibody (Biorad, Cat# MCA1038A488) at 1:25
dilution and incubated for 30 min at room temperature. Cells were washed
and ﬁxed with Foxp3/Transcription Factor Fixation/Permeabilization
buffer (Thermo, Cat# 00-5521-00) and incubated overnight at 4  C. Cells
were washed with 1X permeabilization buffer and stained with 0.5 ug of
anti-mouse/Rat FoxP3 PE antibody (Thermo, Cat# 12–5773) for 30 min at
room temperature. Cells were washed with 1X permeabilization buffer and
analyzed for CD4þFoxP3þ cells by ﬂow cytometry.

2.7. Cytotoxic T lymphocyte (CTL) assay
CTL assays were performed against cryopreserved primary autologous OSA cells isolated from each individual patient dog tumor according
to previous published assay [18]. 5  103 target autologous OSA
cells/well were plated in 96 well plate on day 1 in complete RPMI
(Corning) with penicillin (100 IU/ml, Corning), streptomycin (100
ug/ml, Corning), amphotericin B (0.5ug/ml, Corning), and 20% FBS
(fetal bovine serum, Sigma) at 37  C in T75 cell culture ﬂasks. The next
day, 15ul 51Cr mix (98 μCi in 302μl and 20μl FBS; 3.5uCi/5X103 cells)
added directly to each well for 2 h at 37  C. 51Cr-media was removed and
cells were washed once with RPMI complete media, and post-incubated
in the RPMI-1640 medium for 45 min at 37  C twice to reduce background. Cryopreserved PBMCs were thawed at 37  C and were rested for
1hr on ice in complete RPMI media before adding to the target autologous OSA cells. Effector PBMCs were added in three different ratios
(1:25, 1:50, and 1:100) in three sets of triplicate wells to measure
experimental isotope release for 16h to ensure assay reliability as previously described for canine lymphocytes [19, 20, 21, 21]. Effector
PBMCs were not added in one set of triplicate cells to measure spontaneous isotope release. Cells in another set of triplicate wells were lysed
using lysis buffer (1XPBS þ 10% Triton-X) to measure maximal isotope
release. Supernatants were counted for released radioactivity by liquid
scintillation counting in triplicate. Corrected percent lysis was calculated
to determine relative cytotoxic T-lymphocyte (CTL) activity. Cell mediated immunity was calculated using following formula:

2.8. Statistics
Statistics were performed on the CAV2 titers, CTL assays, and all ﬂow
cytometry data. All the experiments were done in triplicates, except CAV2
titers, which were assessed only one time. Statistical signiﬁcance was
determined using paired t-test. The signiﬁcant threshold was set at p < 0.05.
3. Results
3.1. Virus quantitation
Samples of urine and feces were collected at every 12 h post-virusinjection for viral DNA quantiﬁcation by PCR. Samples of blood were
collected before virus injection, every 12 h after virus injection, and 4
weeks post-injection, just prior to the initiation of chemotherapy. Viral
DNA was weakly positive in urine samples of patients 1, 2, 4, and 8 in
50% or more of the samples collected (Table 2). Viral DNA was transiently expressed in 2 urine samples from patients 3 and 7. Dogs 5, 6, 9,
and 10 showed no detectable shedding in the urine.
Viral DNA was present in occasional fecal samples including a single
time point in dogs 1, 2, 8, and 9 at 24hrs, 108 h, 36 h, and 48 h
respectively (Table 3). Fecal samples from dog 3 were positive at two,
disconnected, time points (12 h, 96 h). Fecal samples from dogs 4 and 10
were positive at three time points. In both cases, two of these time points
were sequential while the third was separated from the others by at least
one time point. Dogs 5, 6, and 7 showed no detectable viral genomes in
their feces.
Viral DNA was not detected in blood samples from any dogs before
virus injection. Viral DNA was detected in the circulation of all dogs
following administration and generally decayed in a logarithmic manner
over the course of the subsequent 6 days (144 h) (Table 4; Figure 1).
Although input doses were identical, initial viral concentrations in blood
post-CRAd administration ranged over more than four orders of magnitude. Initial viral concentrations in blood post-CRAd injection are not
related to the weight of dogs. While most dogs showed small amounts of
variability in the amount of reduction of circulating virus, two dogs
showed clear peaks in viral copy number in their circulation. Dog 2
showed a single elevated sample at 60 h post injection, while dog 6
showed an elevation in viral DNA in circulation beginning at 36 h,
peaking at 48 h and returning to the normal decay curve at 60 h. Virus

%CMI (speciﬁc lysis) ¼ (EIR – SIR/ MIR – SIR) X 100
EIR (experimental isotope release) ¼ Counts per minute (CPMs)
released by CTL-speciﬁc activity in wells with labeled target cells lysed
by PBMCs effector cells.
SIR (spontaneous isotope release) ¼ CPMs released in the absence of
any lysis (negative control) in labeled target cells with no effector cells.
MIR (maximal isotope release) ¼ CPMs released by 10% Triton X-100
lysis of labeled target cells.
Flow Cytometry for Humoral Anti-Tumor Activity, Levels of Antigen
Presenting Cells and Regulatory T Cells.
2.7.1. Humoral anti-tumor activity
Autologous OSA cells were cultured in T75 ﬂasks in complete DMEM
media (as described above). Cells were harvested using 1X trypsin
(Corning). 2.5  105 cells/sample were blocked with blocking buffer (1X
PBS þ 10% FBS þ 0.2ug anti-mouse CD16/CD32; Thermo, Cat# 140161-82) for 1 h at room temperature. Cells were centrifuged and
washed once with wash buffer (1X PBS þ 1% BSA). Cells were incubated
in autologous plasma (pre- and post-injection) for 1 h at room temperature. Cells were washed once with wash buffer and incubated in secondary antibody, goat anti-dog IgG-FITC (Santa Cruz Biotechnology) for
1 h at room temperature. Cells were washed again once with wash buffer
and analyzed for humoral anti-tumor activity by ﬂow cytometry.
4
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Table 2. Quantitation of OC-CAVE1 CRAd genomes in clinical patient's urine using qPCR.
Hours Post Virus-Injection

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

12

4.1

0.53

NS

5.52

0

0

0.50

1.29

NS

0

24

7.4

0.51

0

0.84

0

0

0

0.55

0

0

36

2.8

0.98

NS

0

0

0

0

2.47

0

0

48

3.0

0.91

0

2.1

0

0

0

0

0

0

60

3.6

0.35

NS

0.56

0

0

0

0

0

0

72

9.4

0

0

0.52

0

0

0

4.09

0

0

84

0

0

0

0

0

0

0.83

0

NS

0

96

5

0.23

0.029

0.49

0

NS

0

0

0

0

108

8.6

1.32

NS

1.47

0

0

0

0

0

0

120

NS

0.71

0

0.75

0

0

0

0.70

0

NS

132

0

0.98

0

0.32

0

0

0

0.87

0

0

144

0

1.03

0.005

0

0

0

0

0

0

0

Values are reported as viral copies/ul of sample. A standard curve of known amounts of OC-CAVE1 CRAd template DNA (108, 106, 104, and 102 copies) was used for the
quantiﬁcation reference. NS - no sample collected.

Table 3. Quantitation of OC-CAVE1 CRAd genomes in clinical patient's feces using qPCR.
Hours Post virus-Injection

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

12

19.06

0

1.99

0

0

NS

0

0

NS

0

24

0

0

0

0

0

NS

0

NS

3.44

0

36

0

0

0

0

0

NS

0

7.58

0

0

48

0

0

0

0

0

0

0

NS

0

0

60

0

0

0

0

0

0

0

0

NS

NS

72

0

0

0

0

0

NS

0

0

0

NS

84

0

0

0

0

NS

NS

0

0

0

0.312

96

0

0

3.84

0

0

0

0

NS

0

4

108

0

12.26

0

0.39

0

NS

0

0

NS

NS

120

0

0

0

0

0

NS

0

0

0

NS

132

0

0

0

2.6

0

NS

0

0

NS

11.1

144

0

0

0

0.37

0

NS

0

0

0

NS

Values are reported as viral copies/ug of sample. A standard curve of known amount of OC-CAVE1 CRAd template DNA (108, 106, 104, and 102 copies) was used for the
quantiﬁcation reference. NS - no sample collected.

3.2. Anti-CAV2 titers

remained detectable in the circulation of eight of the ten dogs through
144 h post injection, with only dogs 3 and 10 showing no detectable
circulating viral genomes prior to the end of sampling (132, 144 h),
Subsequently, no virus was present in the blood of any dog 4 weeks postvirus-injection, just prior to the start of chemotherapy.

Pre-existing immune responses to CRAds have been raised as a
possible concern, due to the potential for antibody to CAV2 to remove
CRAd virus from circulation. All of the dogs enrolled in the study had

Table 4. Quantitation of OC-CAVE1 CRAd genomes in clinical patient's blood using qPCR.
Hours Post virus-Injection

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

0

0

0

0

0

0

0

0

0

0

0

12

53800000

5140000

2820000

14520000

426000

14160000

1368000

2940000

850000

1484

24

1880

10620000

458000

3060000

199600

6560000

206000

1042000

46200

412

36

690

4160

60200

464000

288000

12860000

73600

706000

107600

642

48

752

3220

874

71200

54800

85000000

46800

240000

9340

137

60

630

5060000

682

86600

33400

96000

32400

86200

5540

140

72

480

656

470

43400

19480

42200

18220

44400

6920

23

84

262

366

306

18320

6440

2600

7680

51400

2680

8

96

446

444

133

7720

4800

34600

5880

34600

2960

1

108

870

442

84

8140

1108

4080

4520

26600

1416

12

120

138

97

53

3460

964

6540

942

10560

778

1

132

200

63

22

1340

5200

1576

308

8280

366

0

144

38

15

0

1048

1862

612

80.2

5040

252

0

4 weeks

0

0

0

0

0

0

0

0

0

0

Values are reported as viral copies/ul of sample. A standard curve of known amount of OC-CAVE1 CRAd template DNA (108, 106, 104, and 102 copies) was used for the
quantiﬁcation reference.
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Figure 1. Quantitative RT-PCR analysis of OC-CAVE1 CRAd genomes in clinical patient's blood. Absolute quantiﬁcation of CAV2-E1B genomes was determined using
a standard curve.

3.4. Western blot of autologous tumor cell lysates with patient serum

been vaccinated with CAV2 within the previous 3 years. Plasma samples
taken prior to injection and four weeks after CRAD injection were
assessed for CAV-2 neutralizing antibody titers (Figure 2). All dogs,
except dog 8, showed existing anti-CAV2 titers prior to administration of
the CRAd. All dogs showed signiﬁcant increases (Paired T-test; 3.36, Pvalue ¼ .0072) in CAV-2 antibody titers 4 weeks after CRAD-injection.
The fold increase in CAV-2 antibody titers between pre-and post-injection varied from a 5-fold increase in dogs 2, 7, and 9 to a 125-fold increase in dog 3 (Figure 2).

To examine whether OC-CAVE1 CRAd administration generated antibodies against tumor antigens, we compared serum antibody reactivity
against autologous tumor cell lysates between pre-administration and 4
weeks post-administration patient samples. Tumor cell lysates from each
patient were subjected to polyacrylamide gel electrophoresis, blotted
onto membranes, probed with autologous serum, and visualized with an
antibody against canine IgG. Numerous protein bands were visualized in
all of the pre-administration samples, indicating that all of the dogs in the
study had pre-existing circulating antibodies to proteins present in their
tumors (Figure 3). Numerous bands were also visualized with postadministration serum in every dog. Many of the bands seen were present in both the pre- and post-administration samples. However, some of

3.3. Humoral immune responses to tumor
Humoral immune responses to autologous tumor were examined by
two different approaches, Western blot and ﬂow cytometry.

Figure 2. CAV-2 antibody reciprocal titers. Reciprocal anti-CAV2 circulatory neutralizing titers are compared between plasma samples collected before virus-injection
and 4-weeks post-virus injection.
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Figure 3. Western-blot analysis to compare circulating antibodies generated against autologous tumor antigens pre- and post-CRAd administration. For each patient,
autologous blood plasma was used as primary antibody and goat anti-dog IgG-HRP antibody was used as secondary antibody. The blots were scanned using C-Digit
Blot Scanner (LICOR).

of dendritic cells in the circulation reﬂects the antigen presentation status
of the patient. The circulating CD11c-positive population in each patient
dog was quantiﬁed by ﬂow cytometry (Figure 5). There was an increase
in the CD11c þ population in patients 6 and 10. Interestingly, dogs 8 and
9 showed large decreases in their circulating CD11c population after
CRAd administration while dogs 1, 3, 5, and 7 showed smaller decreases.
However, as a group there was no signiﬁcant change in CD11c þ cells in
patients post-administration (Paired T- test; 0.74, P-value, .4770).

the visualized bands were of higher intensities in blots probed with postadministration serum. Examples of this include a band in dog 2 at
approximately 70 kDA (kilodaltons), a band in dog 4 at approximately
20–25 kDA, and a band in dog 6 at approximately 100 kDA. Some bands
appear in similar locations across multiple different dogs, indicating the
potential that one or more common antigens are being recognized
repeatedly.
3.5. Autologous anti-tumor IgG response induced post-vaccination

3.7. Levels of regulatory T cells pre- and post-administration
In order to quantify both the intensity of the anti-tumor IgG response
as well as the proportion of tumor cells recognized by that response, we
developed a ﬂow cytometric protocol to quantify tumor-speciﬁc IgG responses against autologous tumor cells. Autologous plasma from each
dog, obtained pre-administration and 4 weeks post-administration, was
used as the primary antibody to label autologous tumor cells. An anti-dog
IgG secondary antibody labeled with FITC was used to visualize the
labeled cells. The anti-tumor IgG response against autologous tumor cells
showed an increased number of cells staining positive in one patient, dog
1, after treatment (Figure 4A). IgG response against autologous tumor
cells in the remaining dogs did not signiﬁcantly increase post-virus
administration (Paired T-test; -0.98, P-value ¼ .3524). The mean ﬂuorescence intensity of labeling was also examined to determine if the
amount of antibody binding to individual cells had increased (Figure 4B).
The mean ﬂuorescence intensity did not signiﬁcantly increase in the
patients' post-administration (Paired T-test; -1.52, P-value ¼ .1622).

Regulatory T-cells have been implicated in the suppression of antitumor immune responses. The circulating population of T-regs, identiﬁed as CD4þFoxP3þ, was determined by ﬂow cytometry prior to
administration of the CRAd and 4 weeks post-administration (Figure 6).
The percentage of peripheral T-reg cells decreased signiﬁcantly in patients post-CRAd administration (Paired T- test; 3.06, P-value, .0120).
3.8. Cytotoxic activity of tumor antigen-speciﬁc T cells against autologous
tumor cells
Tumor-speciﬁc cytotoxic T lymphocytes are considered to be a major
component of the antitumor immune response. Treatment with CRAds
may stimulate such a response through the induction of local inﬂammation at the site of tumor. Tumor speciﬁc CTL assays were performed by
incubation of 51Cr-loaded autologous tumor cells with PBMC derived
effector cells. Target cell lysis was determined by 51Cr release at effector
cell to target ratios of 25:1, 50:1 and 100:1. Speciﬁc lysis was calculated
as a percentage of released isotope compared to total releasable isotope
available [18] (Figure 7). Lysis rates were low in all cultures, however
some increase in CTL activity were detected in patients 2 and 3. No

3.6. Levels of circulating dendritic cells pre- and post-administration
Dendritic cells, as deﬁned in the dog by a population of cells positive
for CD11c, are a critical component in presenting antigen. The presence

Figure 4. Flow cytometric quantiﬁcation of
the humoral response to autologous OSA
cells. Autologous cells from each patient
were incubated with their own plasma
collected before and 4 weeks after CRAd
administration. Secondary antibody used
was anti-dog IgG-FITC. (A) The graph demonstrates the percent of the population
stained by circulatory antibodies for each
patient pre- and post- CRAd administration.
(B) The graph demonstrates the mean ﬂuorescence intensity of binding of circulatory
antibodies to autologous cells for each patient pre- and post- CRAd administration.
Analysis was done using Accuri ﬂow cytometry software. Error bars represents standard
deviation.
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Figure 5. Flow cytometric quantiﬁcation of
circulatory CD11c þ cells in Osteosarcoma
patients. Blood was collected from patients
and PBMCs were isolated and cryo-preserved
before and after 4 weeks of CRAd administration. The PBMCs were stained for viability
and with anti-canine CD11c antibody tagged
with Zenon ® Alexa Fluor® 700. The graph
demonstrated the percent of population
positive for CD11c staining before and after
CRAd injection. Analysis was done using
Accuri ﬂow cytometry software. Error bars
represents standard deviation.

nodes at the time of enrollment. Following 3 days recovery in the intensive
care unit (ICU), a dose of 2  1012 viral particles of OC-CAVE1 CRAd was
administered intravenously. The dogs were hospitalized, clinically monitored and regularly sampled for an additional 6 days. One dog (Patient 11)
died approximately 12 h after receiving the virus. Post-mortem examination
of this dog revealed signs of gas gangrene, including deep tissue necrosis
and formation of gas pockets in the deep muscle tissues proximal to the
amputation site. Clostridium perfringens was isolated from these tissues. The
cause of death was judged to be due clostridial toxicosis secondary to surgery and the dog was excluded from all subsequent analyses. Vital signs,
CBC, and serum chemistries for the 10 remaining dogs were within normal
limits at every sampling time point. Following this period, the dogs were
discharged to their owners and were asked to return after three weeks to
draw a blood sample before starting on chemotherapy. Dogs were not
monitored after their 4-week visit, for remainder of their survival.

consistent pattern of CTL activity was evident. Cell lysis rates at all three
ratios (1:25, 1:50, and 1:100) were not signiﬁcant as determined by
Paired t-test (1:25, Paired T-test; 0.38, P-value ¼ .7130; 1:50, Paired
T-test; -0.92, P-value ¼ .3823; 1:100, Paired T-test; -0.85, P-value ¼
.4175).
3.9. Enrollment and life span of patients
Eleven client-owned dogs with diagnoses of OSA (biopsy) were enrolled
in the study (Table 1). Ten of those dogs successfully completed the protocol. All the dogs had been administered the canine hepatitis vaccine
(CAV2) within the past 3 years. The affected leg was amputated in 10 dogs.
One dog's (Dog 1) owners elected a limb-sparing surgery to remove the
distal ulnar tumor, leaving the radius intact and the dog weight-bearing.
Dog 7, 8, and 10 had suspected metastasis to lung or regional lymph

Figure 6. Flow cytometric quantiﬁcation of
regulatory T cells in Osteosarcoma patients.
Blood was collected from patients and
PBMCs were isolated and cryo-preserved
before and 4 weeks after CRAd administration. The PBMCs were stained for viability
and with anti-canine CD4:Alexa Fluor® 488
antibody and anti-mouse/Rat FoxP3 PE
antibody. The graph demonstrated the
percent of circulatory CD4þFoxP3þ cells
present before and after CRAd injection.
Analysis was done using Accuri ﬂow cytometry software. Error bars represents standard
deviation.
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Figure 7. Cell mediated immunity of self-circulatory T-cells against autologous tumor cells. PBMCs were isolated and cryopreserved before and after 4 weeks of CRAd
injection. Cytotoxic T lymphocyte (CTL) assays were performed by standard 51Cr-release, using PBMCs cultured with cryopreserved primary autologous OSA cells
isolated from each individual patient dog tumor. CTL activity for each patient was measured in triplicate. CTL activity was calculated as percent-speciﬁc lysis (%CMI)
and total releasable isotope availability for each PBMC:OSA target cell ratio for each patient (1:25, 1:50, and 1:100). All error bars represent standard deviations.

cause of death in dog 4 is unknown and in dog 6 was due to metastatic
tumors (sarcoma) to the skin. This gives an overall 20% greater than oneyear survival.

All 10 dogs that completed the study have now died, allowing complete mortality and longevity data to be collected (Table 1). Dogs 1, 5, 6,
7, 8, and 9 were conﬁrmed to have died from OSA with dogs 2 and 10
conﬁrmed to have died from other causes. The cause of death was not
conﬁrmed in dogs 3 and 4. Median survival time for the 10 dogs in the
study with OSA was 145.5 days, while Mean survival was 208.5 days
(Figure 8). Two of the ten dogs, dogs 4 and 6, survived well past one year,
with survival times of 466 and 524 days (Figure 8). As noted above, the

4. Discussion
OC-CAVE1 is a conditionally replicative canine adenovirus designed
to replicate in cells that express the osteocalcin gene [22], such as OSA.

Figure 8. Survival plot of study patients. The plot is graphed based on the days of survival post-virus injection. Mean survival time of all the dogs enrolled was 208.5
days and the medial survival was 145.5.
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period in excess of a week following injection. However, multiple attempts to culture viable viral particles from feces or urine failed to produce any evidence of viable virus. Human CRAd patients have also not
been documented to transmit CRAds to other people [24].
In response to external antigens, the body's immune system generates
targeted antibodies against the antigen. We hypothesized that in response
to our vector, there would be an enhanced cellular and humoral immune
response against CAV2 and tumor neo-antigens due to enhanced exposure
through cell lysis and the release of cytokines from immune effector cells
upon contact with virus or virus infected cells. Plasma was evaluated for
CAV2 antibody titers. Increases of 5- to 125- fold in reciprocal CAV2
antibody titers in plasma 4 weeks after OC-CAVE1 injection indicates a
strong anamnestic humoral immune response against CAV2.
IgG responses to autologous tumor cells were assessed by Western
blot and ﬂow cytometry. Plasma from patient dogs was used as a primary
polyclonal antibody to perform Western blot analysis with autologous
tumor cell lysates. These blots show multiple bands of interest in both the
pre and 4 weeks post treatment samples. A few of these bands were of
higher intensity when probed with post-virus injection plasma when
compared to pre-injection plasma, indicating that humoral immune responses to some pre-existing antigens were enhanced in some dogs.
Flow cytometry indicated no real difference between the number of
tumor cells recognized by the IgG response against tumor antigens serum
before and after treatment in every dog except dog 1. Dog 1 showed an
increase of nearly 25% in the percentage of cells staining with autologous
serum. Interestingly, dog 1 is the only dog on the study that underwent
limb-sparing surgery and its tumor recurred at the primary site at around
the time that the second sample (4 weeks after virotherapy) was taken.
The dog was euthanized shortly thereafter for progressive disease and
discomfort. Thus, the increase in the number of cells bound by antibody
in this dog may reﬂect a higher antigen load.
These results indicate that OC-CAVE1 CRAd did result both in an
increase in pre-existing anti-tumor humoral responses and the production of antibodies to additional proteins post administration in some
patients. However, the percentage of tumor cells recognized did not increase, nor did there appear to be any survival beneﬁt to any of the
observed humoral responses.
We have also evaluated the levels of dendritic and regulatory T cells
in peripheral blood prior to and following administration of the virus,
using ﬂow cytometry and chromium release assays to monitor cellmediated immune responses.
CD11c is a transmembrane protein expressed on the cell surface of
phagocytic immune cells such as dendritic cells, monocytes, macrophages, and neutrophils. CD11c is the hallmark surface marker of dendritic cells and is used as a dendritic cell speciﬁc cell surface marker along
with MHC class II molecules for ﬂow cytometry quantiﬁcation [25]. In
this study we quantiﬁed the CD11c þ population in order to monitor the
effect of CRAd treatment on antigen presenting cells. Flow cytometry
results indicated an increase in CD11c þ populations in dogs 6 and 10.
Given that dog 6 was a long-term survivor, that might imply a correlation, however, dog 10 was one of the shortest-term survivors, making any
impact of increased dendritic cells difﬁcult to interpret.
Regulatory T cells are a differentiated subset of CD4þ T cells that
have an active role of immune suppression against self-antigens. Differentiated, functional T-reg cells have cell surface receptors CD4 and FoxP3
among others and are associated with suppressed anti-tumor immunity.
Our results indicate that T-reg cell population was signiﬁcantly decreased
in treated patients. These results indicate that T-reg populations in the
circulation may be reduced in response to CRAd treatment, although the
decrease may also be related to the removal of the primary tumor as a
source of PD-L1 or other checkpoint inhibitors [26]. Regardless of the
cause, the decrease in circulating T-regs is promising in that it may
indicate that the immune system in these patients is entering a state
where a functional anti-tumor immune response is possible.
It is important to note that both dendritic and regulatory T-cells are
non-speciﬁc measures of immune response. Given the circumstances in

This CRAd has been shown to effectively kill canine OSA cells in vitro and
in a xenogeneic murine transplant model and has been shown to be safe
in healthy dogs [15, 16]. CRAds such as OC-CAVE1 are hypothesized to
work through several mechanisms. Viral replication leads to cell lysis and
release of additional virus into the cell's microenvironment and the circulation. These new viral particles have the potential to infect new cells.
Existing anti-viral immunity may respond to viral infection and replication in tumor cells with an anti-viral response, leading to additional
tumor cell lysis and the local release of cytokines in the tumor microenvironment. The inﬂammatory response in turn, may shift the tumor
microenvironment to one that supports the expansion of pre-existing
anti-tumor immunity and the induction of novel immune responses
against tumor antigens [23]. Thus, OC-CAVE1 administration may result
in tumor cell killing by a combination of direct lysis, anti-viral immune
responses, and anti-tumor immune responses. Ultimately, these mechanisms may be effective against both primary and metastatic disease.
Based on the potential for anti-tumor immune responses, we designed
a pre-clinical study to evaluate the efﬁcacy of OC-CAVE1 CRAd in
inducing immune responses against potential OSA CSC and metastatic
cells. We enrolled 10 patients in the study over a 2-year span. The dose of
2  1012 virus particles was selected based on the virus safety studies.
That dose was derived by scaling the effective murine dose [16] to an
approximate canine body mass. The rationale for the timing of administration following amputation included the concern that the primary
tumor might serve as a “sink” for virus, removing it from the circulation
and not allowing it to infect metastases and that signiﬁcant killing of
primary tumor could result in tumor lysis syndrome. Administration
immediately following amputation was intended to address micrometastases that are assumed to be present in the vast majority of dogs,
due to their subsequent development of gross metastatic disease. Ten
dogs successfully completed the protocol and have now died, either from
OSA or other causes.
Median survival time for dogs with OSA who receive amputation and
aggressive chemotherapy is approximately 12 months, with 10–15% of
dogs surviving long-term [8, 9, 10]. Median survival time in this study
was 145.5 days and mean survival was 208.5 days, which are both
considerably less than that. This ﬁgure may reﬂect the increased variation present due to the small number of animals enrolled. Two of the ten
dogs, dogs 4 and 6, survived well past one year, with survival times of
466 and 524 days. Thus, the overall conclusion is that treatment with
OC-CAVE1 did not statistically improve lifespan. However, there appears
to a cohort of dogs in this study with relative longevity and the question
must be asked whether that longevity is related to CRAd therapy,
including CRAd induced immunity, or whether these dogs have endogenous mechanisms that allow them to more effectively ﬁght this tumor.
This study did not specify chemotherapeutic regimens to be employed
following the study period so it is recognized that variability or inconsistency in those protocols may also have affected survival times.
Multiplication of virus particles in CSC and metastatic cells is expected in OSA patients. Quantitative PCR indicated that most patients
had circulating viral particles detectable in blood for at least 6 days and
the highest virus DNA amounts in blood at 12 h after virus injection.
However, dogs 2, and 6 had clear viral peaks 48–60 h post infection,
respectively. These peaks show that the virus underwent replication,
which most likely occurred in micrometastases. Dog 6 had the most
obvious peak of viral replication and was the longest survivor in the
study. However, dog 2, who also showed apparent replication, reached
neither the median nor mean survival. The second long-term survivor,
dog 4, did not show an obvious peak of virus, but did have one of the
highest levels of circulating virus over the course of the study.
Virus DNA was identiﬁed sporadically in urine and feces. Fecal or
urinary shedding of viral DNA was not evident in all patients and the
presence of shed DNA did not appear to correlate with any other phenomenon connected with the study. If shed viral DNA represented infectious viral particles, this could represent an infection hazard for other
animals that were exposed to the urine and feces of treated dogs for a
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which these dogs were sampled, immediately following amputation and
4 weeks after administration of the CRAd, there are many additional
factors that could inﬂuence, or mask, these responses, including surgery,
wound healing, and administration of anti-inﬂammatory medicines.
Additionally, time and sampling constraints limited the sampling times.
Ideally, future studies should obtain samples prior to surgery, postsurgery and weekly to assess these and other non-speciﬁc immune
parameters.
Cytotoxic T-cell assays were performed using autologous tumor cells
as targets. These assays indicated the ability of the patient's T-cells to kill
the patient's tumor before and after treatment. Unfortunately, a consistent pattern in CTL activity was not observed in any of the patients except
for an increase in CTL activity in patients 2 and 3. While this increase in
activity is encouraging, it is not correlated with survival.
Dogs 7, 8, and 10 had the appearance of pre-existing metastatic tumor
on chest radiographs, but none of the results of these dogs differed from
dogs with no obvious metastatic growth.
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5. Conclusion
Our study was designed with the hypothesis that intravenous administration of a CAV2 based CRAd, in dogs that had been amputated for primary
OSA, would infect micrometastatic cells and cause cell lysis. This cell lysis
and exposure of viral vector and tumor antigens was hypothesized to induce
humoral and cell mediated immune responses to tumor in patients. While
some encouraging changes in immunological parameters were observed in
this study, there was no measurable impact on survival in the cohort studied. The time of administration of the CRAd was designed to address
micrometastases as rapidly as possible after diagnosis to allow a 4-week
period to study the immune response before administering potentially
immunosuppressive chemotherapy. In reality, it might be better to treat
with chemotherapy ﬁrst and reserve virotherapy for a later time when
metastatic disease is clearly present. However, there was no signiﬁcant effect either in dogs [7, 8, 10] with suspected metastatic growth.
There are multiple other possible explanations for this outcome,
including the small number of animals, relatively slow replication characteristics of this particular CRAd, low levels of activity from the osteocalcin promoter in tumor, too few tumor cells to support replication in
most dogs due to removal of the primary lesion, and a failure to overcome
immune checkpoint inhibitors expressed by tumors, such as PD-L1.
Declarations
Author contribution statement
Payal Agarwal: Conceived and designed the experiments; Performed
the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.
Elizabeth A Gammon: Performed the experiments.
Maninder Sandey, Jey W Koehler: Analyzed and interpreted the data.
Stephanie S Lindley, Brad M Matz, Annette N Smith, Elena A.
Kashentseva, Igor P. Dmitriev, David T Curiel: Contributed reagents,
materials, analysis tools or data.
Bruce F Smith: Conceived and designed the experiments; Analyzed
and interpreted the data; Contributed reagents, materials, analysis tools
or data.
Funding statement
This work was supported by American Kennel Club Canine Health
Foundation (01806).
Data availability statement
Data included in article/supplementary material/referenced in
article.
11

P. Agarwal et al.

Heliyon 7 (2021) e06210
[25] M.P. Poltorak, B.U. Schraml, Fate mapping of dendritic cells, Front. Immunol. 6
(2015) 199.
[26] M. Zuazo, M. Gato-Canas, N. Llorente, M. Ibanez-Vea, H. Arasanz, G. Kochan, et al.,
Molecular mechanisms of programmed cell death-1 dependent T cell suppression:
relevance for immunotherapy Pre-existing Immunity to Oncolytic Virus Potentiates
its Immunotherapeutic Efﬁcacy, Ann. Transl. Med. 5 (19) (2017) 385.

[22] A.S. Wehrle-Martinez, K.E. Dittmer, D. Aberdein, K.G. Thompson, Osteocalcin and
osteonectin expression in canine osteosarcoma, Veterinary pathology 53 (4) (2016)
781–787.
[23] J.M. Ricca, A. Oseledchyk, T. Walther, C. Liu, L. Mangarin, T. Merghoub, et al., Preexisting immunity to oncolytic virus potentiates its immunotherapeutic efﬁcacy,
Mol. Ther. – J. Am. Soc. Ther. 26 (4) (2018) 1008–1019.
[24] W.S. Wold, K. Toth, Adenovirus vectors for gene therapy, vaccination and cancer
gene therapy, Curr. Gene Ther. 13 (6) (2013) 421–433.

12

